Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Anti-Human SIGLEC10/SLG2 Antibody (ONC-841)

Catalog #:   DHJ40401 Specific References (33) DATASHEET
Host species: Human
Isotype: IgG
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHJ40401

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG

Clonality

Monoclonal

Target

SIGLEC10, Siglec-10, Sialic acid-binding Ig-like lectin 10, Siglec-like protein 2, SLG2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q96LC7

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

ONC-841

Data Image
References

Sonocatalytic oncolysis microbiota curb intrinsic microbiota lactate metabolism and blockade CD24-Siglec10 immune escape to revitalize immunological surveillance., PMID:38878482

Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer., PMID:38652971

Proinflammatory polarization strongly reduces human macrophage in vitro phagocytosis of tumor cells in response to CD47 blockade., PMID:38593339

Checkpoint CD24 function on tumor and immunotherapy., PMID:38487533

Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions., PMID:38279998

RARγ promotes the invasion and metastasis of thyroid carcinoma by activating the JAK1-STAT3-CD24/MMPs axis., PMID:37897947

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy., PMID:37846296

The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells., PMID:37504378

New hope for tumor immunotherapy: the macrophage-related "do not eat me" signaling pathway., PMID:37484024

The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia., PMID:37424400

Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway., PMID:36866919

Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation., PMID:36736908

Single-cell RNA sequencing identifies precise tolerogenic cellular and molecular pathways induced by depigmented-polymerized grass pollen allergen extract., PMID:36649758

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma., PMID:35625912

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma., PMID:35317832

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology., PMID:35012610

Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma., PMID:34112250

CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function., PMID:33658999

A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides., PMID:33223341

Expression of Siglec-1, -3, -5 and -10 in porcine cDC1 and cDC2 subsets from blood, spleen and lymph nodes and functional capabilities of these cells., PMID:32234314

Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression., PMID:31534365

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy., PMID:31367043

CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function., PMID:29997173

Molecular characterization of porcine Siglec-10 and analysis of its expression in blood and tissues., PMID:25280627

SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders., PMID:24859880

Immune regulation by CD52-expressing CD4 T cells., PMID:23934027

Role of inhibitory BCR co-receptors in immunity., PMID:22394175

Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction., PMID:21478876

CD24 and Siglec-10 selectively repress tissue damage-induced immune responses., PMID:19264983

Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells., PMID:16677248

Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters., PMID:11579105

Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells., PMID:11358961

Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor., PMID:11284738

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Anti-Human SIGLEC10/SLG2 Antibody (ONC-841) [DHJ40401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only